Mavenir and Terrestar Solutions Partner to Accelerate Commercial Deployment of 5G New Radio Non-Terrestrial Network
23.2.2024 18:49:00 EET | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, continues its pioneering leadership in Open RAN with 5G New Radio (NR) Non-Terrestrial-Network (NTN) solutions. The latest initiative is to integrate satellite connectivity for Open RAN terrestrial networks thereby enabling seamless connectivity for users across satellite and terrestrial networks. The project is being delivered in collaboration with Terrestar Solutions, a Canadian based Satellite Operator.
Satellite Operators are actively looking at ways to harness 5G NTN capabilities within their network topology, to extend coverage and capacity in areas where traditional terrestrial networks may be economically unfeasible or impractical. Terrestar will launch a new Narrowband IoT (NB-IoT) service offer to the market, evolving to a full 5G Direct to Device (D2D) service by 2025. As the chosen technology supplier, Mavenir will provide the enabling 3GPP standards-compliant Core and O-RAN interface technology. Open RAN implementations, aligned to the O-RAN alliance specifications, are driving the deployment of open, intelligent, and secure networks for both mobile network and satellite network owners.
Jacques Leduc, President and CEO of Terrestar Solutions, announced, “This partnership aims to develop interoperable standards that seamlessly link multi-orbit satellite systems, ground infrastructure, and mobile devices together. This initiative is a pivotal step towards ensuring every Canadian enjoys seamless, high-quality connectivity, directly benefiting both industries and consumers."
Pardeep Kohli, CEO at Mavenir, said, “Mavenir's O-RAN, built on ETSI O-RAN 3GPP R.17 standards, makes it possible to integrate terrestrial and satellite service points quickly and seamlessly. Working with our partner Terrestar, this project showcases the remarkable flexibility that can be achieved through this standard and technology. Open RAN deployments are demonstrating their clear potential for enabling unprecedented levels of connectivity for consumers and industries, surpassing the possibilities of traditional RAN software builds.”
About Terrestar Solutions
Terrestar Solutions Inc. is a Canadian mobile satellite operator engaged in the race to bring direct-to-device satellite services to smartphones and IoT devices and make anywhere in Canada communication a reality. The Company is committed to nurturing the ever-evolving, standards-based and open network ecosystem, enabling Mobile Network Operators to deliver ubiquitous communication services. Thanks to the Echostar T1 satellite, its ground network infrastructure and mobile satellite spectrum, Terrestar connects Canadians from almost anywhere in the country, even in Canada’s most remote regions through its Strigo Mobile Satellite Service (MSS). The Strigo service also supports non-profit and First Nations organizations, a testament to the Company’s strong sense of responsibility towards the welfare and progress of the communities it serves. For more information, visit www.terrestarsolutions.ca, contact media@terrestarsolutions.ca, or follow us on LinkedIn.
About Mavenir
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223235087/en/
Contact information
Terrestar PR Contact:
Victoria Ollers
Terrestar Solutions
vicki.ollers@terrestar.ca
Mavenir PR Contact:
Emmanuela Spiteri
pr@mavenir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom